Posted by Michael Wonder on 29 Oct 2024
People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy
29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE recommended a new targeted treatment for use within the Cancer Drugs Fund today.
Just over 700 people in England are eligible to benefit from elranatamab for multiple myeloma that has returned and stopped responding to previous treatments, and who have had at least three lines of other kinds of treatment and whose cancer has worsened since receiving the last treatment.
